Related Experiment Video
Updated: Jun 29, 2025
09:20
Lumped-Parameter and Finite Element Modeling of Heart Failure with Preserved Ejection Fraction
Published on: February 13, 2021
6.4K
Guideline-directed device therapies in heart failure: A clinical practice-based analysis using electronic health
Anne B Curtis1, Christopher Manrodt2, Luke D Jacobsen2
1Jacobs School of Medicine and Biomedical Sciences, University at Buffalo, Buffalo, NY, United States of America.
Summary
Guideline-directed device therapies (GDDT) like ICDs and CRT-Ds are underutilized in eligible heart failure patients. Many patients received other indicated treatments, but not these life-saving devices.
Area of Science:
- Cardiology
- Medical Devices
- Heart Failure Management
Background:
- Guideline-directed device therapies (GDDT) improve outcomes in heart failure with reduced ejection fraction (HFrEF).
- Utilization rates of GDDT in HFrEF post-2012 guidelines are not well-studied.
Purpose of the Study:
- To characterize the utilization of GDDT in newly indicated HFrEF patients between 2012 and 2019.
- To analyze trends in device therapy adoption using electronic health record (EHR) data.
Main Methods:
- Employed computable phenotyping algorithms (GLIDE-HF) on de-identified EHR data.
- Included HFrEF patients with new Class 1 or 2a indications for ICD or CRT-D from 2012-2019.
Main Results:
- 137,476 HFrEF patients were newly indicated for ICD or CRT-D.
- GDDT use was 41.0% for CRT-D and 14.7% for ICD indications.
- High rates of echocardiography (95.7%) and guideline-indicated medications (92.1%) were observed.
Conclusions:
- A significant proportion of eligible HFrEF patients did not receive ICDs or CRT-Ds.
- Other guideline-indicated cardiovascular interventions and treatments were frequently administered.
Related Concept Videos
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
424
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
424
01:26Heart Failure Drugs: Inotropic Agents
578
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
578
01:22Heart Failure Drugs: β-Blockers
337
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
337
01:30Pulse rhythm
795
Pulse rhythm refers to the pattern of pulsations within specific intervals, offering valuable insights into the regularity or irregularity of the heart's beats as observed through the pattern of pulsation within specific intervals. A regular pulse exhibits a consistent heart rate with uniform waveforms and pulsation force, variations of which can be classified as normal, weak, or bounding.
Conversely, an irregular pulse pattern is termed dysrhythmia, stemming from disruptions in cardiac...
Conversely, an irregular pulse pattern is termed dysrhythmia, stemming from disruptions in cardiac...
795
01:22Heart Failure Drugs: Diuretics
370
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
370
01:17Pathophysiology of Heart Failure
1.6K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
1.6K